State of the Art REVIEW
188 Kandane-Rathnayake R, Louthrenoo W, Luo SF, et al, Asia-Pacific Lupus Collaboration. Patterns of medication use in systemic lupus erythematosus: a multicenter cohort study. Arthritis Care Res (Hoboken) 2022;74:2033-41. doi:10.1002/acr.24740. 189 Rovin BH, Adler SG, Barratt J, et al, Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100(4S):S1-276. doi:10.1016/j. kint.2021.05.021. 190 Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713-23. doi:10.1136/ annrheumdis-2020-216924. 191 McCarthy EM, Sutton E, Nesbit S, et al, British Isles Lupus Assessment Group Biologics Register. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford) 2018;57:470-9. doi:10.1093/ rheumatology/kex395. 192 Aguiar R, Araújo C, Martins-Coelho G, Isenberg D. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken) 2017;69:257-62. doi:10.1002/ acr.22921. 193 Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51. doi:10.1002/art.24698. 194 Doria A, Stohl W, Schwarting A, et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol 2018;70:1256-64. doi:10.1002/art.40511. 195 Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016-27. doi:10.1002/art.40049. 196 Brunner HI, Abud-Mendoza C, Viola DO, et al, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo- controlled trial. Ann Rheum Dis 2020;79:1340-8. doi:10.1136/ annrheumdis-2020-217101. 197 Joy A, Muralidharan A, Alfaraj M, Shantharam D, Cherukuri ASS, Muthukumar A. The role of belimumab in systemic lupus erythematosis: a systematic review. Cureus 2022;14:e25887. doi:10.7759/cureus.25887. 198 Urowitz MB, Ohsfeldt RL, Wielage RC, Kelton KA, Asukai Y, Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis 2019;78:372-9. doi:10.1136/ annrheumdis-2018-214043. 199 Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon- alpha receptor monoclonal antibody, in moderate to severe SLE. Arthritis Rheum 2017;69:376-86. doi:10.1002/art.39962. 200 Morand EF, Furie RA, Bruce IN, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol 2022;4: E282-92. doi:10.1016/S2665-9913(21)00317-9. 201 Furie R, Morand EF, Askanase AD, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 2021;30:1254-63. doi:10.1177/09612033211014267. 202 Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 2021;8:e000464. doi:10.1136/ lupus-2020-000464. 203 Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo- controlled phase iii extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol 2023;75:253-65. doi:10.1002/art.42392. 204 Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 2020;79:1070-6. doi:10.1136/ annrheumdis-2020-217178. 205 Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al, Asia-Pacific Lupus Collaboration. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther 2022;24:70. doi:10.1186/s13075-022-02756-3. 206 Sharma C, Raymond W, Eilertsen G, Nossent J. Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus
169 Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 2023;82:639-45. doi:10.1136/ard-2022-222748. 170 Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis 2019;78:629-33. doi:10.1136/annrheumdis-2018-214427. 171 Morand EF, Trasieva T, Berglind A, et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis 2018;77:706-13. doi:10.1136/ annrheumdis-2017-212504. 172 Almeida-Brasil CC, Hanly JG, Urowitz M, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 2022;81:370-8. doi:10.1136/ annrheumdis-2021-221295. 173 Jorge A, McCormick N, Lu N, et al. Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population. Arthritis Care Res (Hoboken) 2021;73:1219-23. doi:10.1002/acr.24255. 174 Blanchet B, Jallouli M, Allard M, et al, PLUS Group. Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Res Ther 2020;22:223. doi:10.1186/s13075-020-02291-z. 175 Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90. doi:10.1002/art.22156. 176 Jallouli M, Francès C, Piette JC, et al, Plaquenil LUpus Systemic Study Group. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 2013;149:935-40. doi:10.1001/jamadermatol.2013.709 178 Rosenbaum JT, Costenbader KH, Desmarais J, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol 2021;73:908-11. doi:10.1002/ art.41683 179 Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736-45. doi:10.1136/ annrheumdis-2019-215089. 180 Hahn BH, McMahon MA, Wilkinson A, et al, American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797-808. doi:10.1002/acr.21664. 181 Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol 2020;2:e24-30. doi:10.1016/S2665-9913(19)30105-5. 182 Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015;74:1706-13. doi:10.1136/annrheumdis-2013-205171. 183 Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol 2020;2:e24-30. doi:10.1016/S2665-9913(19)30105-5. 184 Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:1470-6. doi:10.1093/rheumatology/keu148. 185 Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 2020;79:339-46. doi:10.1136/annrheumdis-2019-216303. 186 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Enteric-coated 177 Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453-60. doi:10.1001/ jamaophthalmol.2014.3459. mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 2017;76:1575-82. doi:10.1136/ annrheumdis-2016-210882. 187 Wahadat MJ, van den Berg L, Timmermans D, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med 2021;8:e000571. doi:10.1136/lupus-2021-000571.
the bmj | BMJ 2023;383:073980 | doi: 10.1136/bmj-2022-073980
19
Powered by FlippingBook